Table 5 Pairwise comparison of the recommendations from the index MDT versus ESMO and NCCN guidelines
Treatment Modality | Agreement between the expertise | |||||
|---|---|---|---|---|---|---|
Strategy | MDT versus ESMO | MDT versus NCCN | ESMO versus NCCN | |||
N | (%) | N | (%) | N | (%) | |
Chemotherapy | ||||||
Overalla | 551/975 | (57) | 462/975 | (47) | 320/1065 | (30) |
Aggressive | 628/975 | (64) | 616/975 | (63) | 416/1065 | (39) |
Conservative | 729/975 | (75) | 731/975 | (75) | 721/1065 | (68) |
Endocrine therapy | ||||||
Overalla | 853/1002 | (85) | 840/1002 | (84) | 976/1065 | (92) |
Aggressive | 970/1002 | (97) | 953/1002 | (95) | 1024/1065 | (96) |
Conservative | 858/1002 | (86) | 861/1002 | (86) | 976/1065 | (92) |
Trastuzumab | ||||||
Overalla | 437/456 | (96) | 437/456 | (96) | 1047/1065 | (98) |
Aggressive | 444/456 | (97) | 446/456 | (98) | 1058/1065 | (99) |
Conservative | 437/456 | (98) | 440/456 | (97) | 1047/1065 | (98) |